Given the remarkable reversion and inhibitory effect of LY on CAFs and the TGF-β/Smad signaling pathway, the next was to accomplish the tumor-specific delivery of LY for recruiting tumor-specific T lymphocytes. This evidence concerns the gene TGFB1 and neoplasm.